Literature DB >> 14669277

Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.

Masood A Khan1, Patrick C Walsh, M Craig Miller, Wesley D Bales, Jonathan I Epstein, Leslie A Mangold, Alan W Partin, Robert W Veltri.   

Abstract

BACKGROUND: Microscopic histologic grade has been the best predictor of prostate carcinoma (PCa) progression in men after surgical therapy. The ability to predict accurately, at the time of surgery, which patients are likely to develop metastatic PCa would enable optimization of disease management with adjuvant therapy. The authors assessed the ability of pathologic, nuclear morphometric, and chromatin parameters to predict metastatic PCa progression and/or death in 227 men with biochemical recurrence and long-term follow-up after undergoing radical prostatectomy.
METHODS: Multivariate logistic regression (LR) was used to calculate quantitative nuclear grade (QNG) solutions using the variances of 60 nuclear morphometric descriptors (NMDs) of nuclear size, shape, DNA content, and chromatin organization that predicted distant metastasis and/or PCa-specific death. An LR model also was generated to predict this outcome using a combination of pathologic variables and the best QNG solution. Cox proportional hazards models were generated, and Kaplan-Meier plots were used to display three risk groups based on pathology, QNG, and a combination of these variables.
RESULTS: A multivariate LR model using pathology retained lymph node (LN) status, seminal vesicle status, and prostatectomy Gleason score, yielding an area under the curve-receiver operator characteristic (AUC-ROC) of 75% with an accuracy of 59% at 90% sensitivity. The best QNG solution used the variance of 25 NMDs, yielding an AUC-ROC of 84% and an accuracy of 70% at 90% sensitivity. The combined pathology-QNG model retained LN status, prostatectomy Gleason score, and QNG, yielding an AUC-ROC of 86% with an accuracy of 76% at 90% sensitivity. The Cox proportional hazards models produced the following significant univariate and multivariate hazard ratios: QNG, 3.5 and 2.9, respectively; LN, 2.7 and 1.8, respectively; and prostatectomy Gleason score, 2.8 and 2.1, respectively.
CONCLUSIONS: Alterations in the structure of tumor nuclei measured by computer-assisted image analysis were strong predictors of PCa progression and death in men with long-term follow-up who had biochemical recurrence after undergoing radical prostatectomy. QNG solutions can serve as a new supplemental biomarker for accurate prediction of PCa progression at the time of surgery. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669277     DOI: 10.1002/cncr.11852

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Nuclear morphometry, nucleomics and prostate cancer progression.

Authors:  Robert W Veltri; Christhunesa S Christudass; Sumit Isharwal
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

2.  Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.

Authors:  Jie-Fu Chen; Hao Ho; Jake Lichterman; Yi-Tsung Lu; Yang Zhang; Mitch A Garcia; Shang-Fu Chen; An-Jou Liang; Elisabeth Hodara; Haiyen E Zhau; Shuang Hou; Rafi S Ahmed; Daniel J Luthringer; Jiaoti Huang; Ker-Chau Li; Leland W K Chung; Zunfu Ke; Hsian-Rong Tseng; Edwin M Posadas
Journal:  Cancer       Date:  2015-05-14       Impact factor: 6.860

3.  Fusion between tumor cells enhances melanoma metastatic potential.

Authors:  Ruifang Mi; Chunxiao Pan; Xiaocui Bian; Liqiang Song; Wenjia Tian; Fang Cao; Juan Yin; Haiyong Peng; Jianhui Ma
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-24       Impact factor: 4.553

4.  Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning.

Authors:  Girish Venkataraman; Vijayalakshmi Ananthanarayanan; Gladell P Paner; Rui He; Saeedeh Masoom; James Sinacore; Robert C Flanigan; Eva M Wojcik
Journal:  Virchows Arch       Date:  2006-08-03       Impact factor: 4.064

5.  A Cell-Free Assay Using Xenopus laevis Embryo Extracts to Study Mechanisms of Nuclear Size Regulation.

Authors:  Lisa J Edens; Daniel L Levy
Journal:  J Vis Exp       Date:  2016-08-08       Impact factor: 1.355

Review 6.  Advances in the computational and molecular understanding of the prostate cancer cell nucleus.

Authors:  Neil M Carleton; George Lee; Anant Madabhushi; Robert W Veltri
Journal:  J Cell Biochem       Date:  2018-06-20       Impact factor: 4.429

7.  Nuclear grading versus Gleason grading in small samples containing prostate cancer: a tissue microarray study.

Authors:  Daniel Wittschieber; Jens Köllermann; Thorsten Schlomm; Guido Sauter; Andreas Erbersdobler
Journal:  Pathol Oncol Res       Date:  2010-04-23       Impact factor: 3.201

8.  p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.

Authors:  Sumit Isharwal; Michael C Miller; Cameron Marlow; Danil V Makarov; Alan W Partin; Robert W Veltri
Journal:  Prostate       Date:  2008-07-01       Impact factor: 4.104

9.  Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.

Authors:  Daniel T Keefe; Nicola Schieda; Soufiane El Hallani; Rodney H Breau; Chris Morash; Susan J Robertson; Kien T Mai; Eric C Belanger; Trevor A Flood
Journal:  Virchows Arch       Date:  2015-07-31       Impact factor: 4.064

10.  Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.

Authors:  Danil V Makarov; Cameron Marlow; Jonathan I Epstein; M Craig Miller; Patricia Landis; Alan W Partin; H Ballentine Carter; Robert W Veltri
Journal:  Prostate       Date:  2008-02-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.